Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2789 | PROTECTIVE VENTILATION Wiki | 1.00 |
| drug4125 | ULTRAPROTECTIVE VENTILATION Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
This study tests the randomized re-opening of training facilities in Norway in relation to the COVID-19 pandemic. The investigators will use the recently developed concept of rapid-cycle randomized implementation to assure fast and safe re-introduction of training facilities by randomized testing of access restriction and measure virus exposure and immunity as well as clinical disease during the intervention to enable safe and timely downgrading of COVID-19 restrictions. Members of training facilities in Norway age 18 to 64 years without COVID-19 related comorbidity will after informed consent be randomised to either access to training or no access in a first 2-week cycle. Testing for COVID-19 and ascertainment of clinical disease will be performed after the first cycle. If there is no clinically meaningful difference between the arms, new cycles may be implemented subsequently, e.g. with less distancing restrictions or wider age groups.
Description: Percentage of COVID-19 RNA positive individuals
Measure: COVID-19 RNA test positivity Time: At the end of Cycle 1 (cycle length is 14 days)Description: Percentage of people admitted to hospital for COVID-19
Measure: Hospital admission for COVID-19 Time: 7 days after the end of Cycle 1 (cycle length is 14 days)Description: Percentage of individuals with COVID-19 antibodies by blood sampling
Measure: individuals with COVID-19 antibodies Time: 14 to 20 days after the end of Cycle 1 (cycle length is 14 days)Description: Percentage of people who had any contacs with primary or secondary health care services
Measure: Percentage of individuals with health care contacts Time: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)Description: Percentage of people in need of ventilator after hosital admission for COVID-19
Measure: Need of ventilator treatment after hospital admission for COVID-19 Time: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)Description: Percentage of people admitted to the ICU for COVID-19
Measure: ICU admission for COVID-19 Time: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)Description: Percentage of people who died, with cause of death (including underlying cause of death)
Measure: Cause-specific death Time: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)Description: Percentage of COVID-19 RNA positive employees who worked at the training centres during the intervention
Measure: COVID-19 RNA test positivity in employees at training centres Time: At the end of Cycle 1 (cycle length is 14 days)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports